Header Logo

Matthew Silva

Concepts (161)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Pharmacists
6
2023
122
1.020
Why?
Community Health Centers
3
2013
89
0.790
Why?
Public Health
2
2013
174
0.720
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
3
2007
206
0.650
Why?
Exercise
4
2013
883
0.600
Why?
Telemedicine
1
2023
307
0.600
Why?
Anticoagulants
5
2020
477
0.590
Why?
Platelet Aggregation Inhibitors
4
2013
211
0.590
Why?
Medicare Part D
1
2017
37
0.570
Why?
Cost Savings
1
2017
52
0.560
Why?
Primary Health Care
2
2013
643
0.550
Why?
Diabetes Mellitus, Type 2
1
2023
635
0.530
Why?
Hypercholesterolemia
2
2007
68
0.510
Why?
Polypharmacy
1
2016
61
0.500
Why?
Platelet Glycoprotein GPIIb-IIIa Complex
2
2006
23
0.490
Why?
Aspirin
2
2013
166
0.490
Why?
Pancreatitis
1
2016
95
0.490
Why?
Venous Thromboembolism
4
2020
141
0.440
Why?
Ticlopidine
3
2013
45
0.440
Why?
Warfarin
2
2014
105
0.430
Why?
Antipsychotic Agents
1
2016
292
0.420
Why?
Stroke
3
2013
1127
0.330
Why?
Anticholesteremic Agents
1
2007
34
0.270
Why?
Hemorrhage
6
2018
260
0.260
Why?
Humans
26
2023
59360
0.240
Why?
Angioplasty, Balloon, Coronary
1
2006
167
0.240
Why?
Atrial Fibrillation
1
2013
805
0.240
Why?
Angina, Unstable
1
2004
56
0.230
Why?
Coronary Disease
1
2006
244
0.230
Why?
Randomized Controlled Trials as Topic
8
2018
677
0.230
Why?
Tyrosine
1
2004
92
0.230
Why?
Anemia, Hemolytic, Congenital Nonspherocytic
1
2023
3
0.220
Why?
Anemia, Hemolytic
1
2023
12
0.220
Why?
Coronary Artery Disease
3
2016
273
0.210
Why?
C-Reactive Protein
1
2004
159
0.210
Why?
Quinolones
1
2023
27
0.210
Why?
Pharmacy Service, Hospital
1
2003
20
0.210
Why?
Computers, Handheld
1
2003
38
0.210
Why?
Anemia, Sickle Cell
1
2023
61
0.210
Why?
Vulnerable Populations
1
2023
84
0.200
Why?
Urban Population
1
2023
179
0.200
Why?
Documentation
1
2003
127
0.200
Why?
Diabetes Mellitus
2
2008
515
0.180
Why?
Pharmaceutical Services
2
2017
31
0.160
Why?
Retrospective Studies
2
2023
6071
0.160
Why?
Pandemics
1
2023
615
0.150
Why?
Continuity of Patient Care
1
2020
170
0.150
Why?
Myocardial Infarction
1
2004
862
0.150
Why?
Clinical Trials as Topic
3
2006
441
0.140
Why?
Pharmacies
1
2017
34
0.140
Why?
Male
11
2020
27739
0.140
Why?
Rivaroxaban
2
2014
19
0.130
Why?
Dabigatran
2
2014
20
0.130
Why?
Pyridones
2
2014
37
0.130
Why?
Female
11
2020
30705
0.130
Why?
Pyrazoles
2
2014
65
0.130
Why?
Hospitalization
3
2020
1290
0.130
Why?
Patient Education as Topic
1
2020
453
0.130
Why?
Benzazepines
1
2016
21
0.130
Why?
Massachusetts
3
2017
2002
0.120
Why?
Adult
7
2023
15669
0.120
Why?
Aged
6
2017
13416
0.120
Why?
Data Interpretation, Statistical
2
2013
191
0.120
Why?
Ventricular Dysfunction, Left
1
2016
158
0.110
Why?
Schizophrenia
1
2016
242
0.110
Why?
Dipyridamole
1
2013
17
0.110
Why?
Databases, Bibliographic
1
2013
7
0.110
Why?
beta-Alanine
1
2013
8
0.110
Why?
Thiophenes
1
2013
29
0.110
Why?
Drug Therapy, Combination
3
2013
452
0.100
Why?
Morpholines
1
2013
86
0.100
Why?
Benzimidazoles
1
2013
56
0.100
Why?
Proline
1
2013
42
0.100
Why?
Secondary Prevention
1
2013
151
0.100
Why?
Fees and Charges
1
2012
18
0.100
Why?
Treatment Outcome
3
2016
5284
0.100
Why?
Oligopeptides
1
2013
128
0.100
Why?
Protease Inhibitors
1
2013
104
0.100
Why?
Anti-Ulcer Agents
1
2011
8
0.100
Why?
Hepatitis C, Chronic
1
2013
88
0.100
Why?
Emergency Service, Hospital
1
2020
1021
0.100
Why?
Middle Aged
7
2016
16317
0.100
Why?
Students, Pharmacy
1
2011
12
0.090
Why?
Ambulatory Care Facilities
1
2012
102
0.090
Why?
Double-Blind Method
1
2013
715
0.090
Why?
Inappropriate Prescribing
1
2011
64
0.090
Why?
Community Health Services
1
2012
120
0.090
Why?
Motor Activity
1
2012
333
0.080
Why?
Sex Factors
1
2012
935
0.080
Why?
Education, Pharmacy, Graduate
1
2009
4
0.080
Why?
Risk Factors
3
2013
4984
0.080
Why?
Education, Pharmacy, Continuing
1
2009
3
0.080
Why?
Medical Waste Disposal
1
2009
3
0.080
Why?
Mental Disorders
1
2016
717
0.080
Why?
Age Factors
1
2012
1504
0.080
Why?
Health Promotion
1
2012
471
0.070
Why?
Young Adult
2
2016
4267
0.070
Why?
Fellowships and Scholarships
1
2009
98
0.070
Why?
Program Development
1
2009
203
0.070
Why?
Adolescent
2
2016
5824
0.070
Why?
Child
1
2016
4174
0.070
Why?
United States
2
2017
7390
0.070
Why?
Cooperative Behavior
1
2008
210
0.070
Why?
Rhabdomyolysis
1
2006
21
0.060
Why?
Poverty
1
2008
281
0.060
Why?
Quality Assurance, Health Care
1
2008
251
0.060
Why?
Syndrome
1
2006
170
0.060
Why?
Drug Administration Schedule
1
2006
283
0.060
Why?
Dose-Response Relationship, Drug
1
2007
806
0.060
Why?
Immunoglobulin Fab Fragments
1
2004
36
0.060
Why?
Diabetes Complications
1
2004
100
0.060
Why?
Acute Disease
1
2006
660
0.060
Why?
Health Knowledge, Attitudes, Practice
1
2009
724
0.050
Why?
Pyruvate Kinase
1
2023
11
0.050
Why?
Hemolysis
1
2023
38
0.050
Why?
Guideline Adherence
1
2006
290
0.050
Why?
Prospective Studies
2
2011
3067
0.050
Why?
Reimbursement Mechanisms
1
2003
40
0.050
Why?
Research Design
1
2006
555
0.050
Why?
Incidence
1
2006
1237
0.050
Why?
Registries
1
2006
801
0.050
Why?
Practice Guidelines as Topic
1
2006
705
0.050
Why?
Peptides
1
2004
549
0.050
Why?
Antibodies, Monoclonal
1
2004
839
0.040
Why?
Cardiovascular Diseases
1
2007
788
0.040
Why?
Home Care Services
1
2020
97
0.040
Why?
Premedication
1
2018
16
0.040
Why?
Patient Discharge
1
2020
489
0.030
Why?
Adrenergic beta-Antagonists
1
2016
147
0.030
Why?
Heart Rate
1
2016
307
0.030
Why?
Administration, Oral
1
2014
356
0.030
Why?
Clinical Trials, Phase II as Topic
1
2013
23
0.030
Why?
Ribavirin
1
2013
24
0.030
Why?
Clinical Trials, Phase III as Topic
1
2013
40
0.030
Why?
Interferon-alpha
1
2013
99
0.020
Why?
Precision Medicine
1
2013
102
0.020
Why?
Interinstitutional Relations
1
2012
37
0.020
Why?
Polyethylene Glycols
1
2013
165
0.020
Why?
Recombinant Proteins
1
2013
689
0.020
Why?
Internal Medicine
1
2011
154
0.020
Why?
Academic Medical Centers
1
2012
306
0.020
Why?
Blood Coagulation Tests
1
2009
5
0.020
Why?
Platelet Aggregation
1
2009
23
0.020
Why?
Environmental Pollution
1
2009
12
0.020
Why?
Training Support
1
2009
19
0.020
Why?
Drug Industry
1
2009
39
0.020
Why?
Electronic Health Records
1
2011
342
0.020
Why?
Heart Failure
1
2016
853
0.020
Why?
Guidelines as Topic
1
2009
154
0.020
Why?
Community Participation
1
2008
45
0.020
Why?
Heparin, Low-Molecular-Weight
1
2007
26
0.020
Why?
Pharmaceutical Preparations
1
2009
117
0.020
Why?
Health Services Accessibility
1
2012
521
0.020
Why?
Data Collection
1
2009
371
0.020
Why?
Drug Utilization
1
2007
208
0.020
Why?
Cohort Studies
1
2011
2374
0.020
Why?
Odds Ratio
1
2007
745
0.020
Why?
Thrombosis
1
2007
182
0.020
Why?
Pulmonary Embolism
1
2007
170
0.020
Why?
Attitude of Health Personnel
1
2009
550
0.010
Why?
Aged, 80 and over
1
2008
5128
0.010
Why?
Silva's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (161)
Explore
_
Co-Authors (10)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_